Huttig Building Products, Inc. HBP
Set alert
10.70 0.00 0.00%
As of Apr 24, 3:47 PM ET
10.68 Day range 10.70
52-week range unavailable
- Open
- 10.68
- Prev close
- 10.70
- Mkt cap
- 292.40M
- Vol
- 304.28K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 10.68
- High
- 10.70
- Forward P/E
- 20.19
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 2, 2022
- 50-d avg
- 10.14
- 200-d avg
- 8.35
- 1y target
- 0.00
2Y chart
Events in this range
- Nov 3, 2021Earnings: —; estimate 0; surprise —%
- Mar 2, 2022Earnings: —; estimate 0; surprise —%
- May 2, 2022Earnings: —; estimate 0; surprise —%
Signals (23)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Apr 11, 2022 | 4 years ago |
| SMA: Bullish | Mar 18, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 18, 2022 | 4 years ago |
| MACD: Sell Signal | Mar 7, 2022 | 4 years ago |
| SMA: Bearish | Mar 4, 2022 | 4 years ago |
| MACD: Buy Signal | Mar 3, 2022 | 4 years ago |
| SMA: Bullish | Mar 2, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 23, 2022 | 4 years ago |
| SMA: Bearish | Feb 18, 2022 | 4 years ago |
| SMA: Bullish | Feb 15, 2022 | 4 years ago |
| SMA: Bearish | Feb 11, 2022 | 4 years ago |
| SMA: Bullish | Feb 9, 2022 | 4 years ago |
| SMA: Bearish | Feb 4, 2022 | 4 years ago |
| MACD: Buy Signal | Feb 2, 2022 | 4 years ago |
| SMA: Bullish | Feb 1, 2022 | 4 years ago |
| SMA: Bearish | Jan 18, 2022 | 4 years ago |
| MACD: Sell Signal | Jan 5, 2022 | 4 years ago |
| RSI: Overbought | Dec 30, 2021 | 4 years ago |
| RSI: Overbought | Dec 23, 2021 | 4 years ago |
| MACD: Buy Signal | Dec 21, 2021 | 4 years ago |
| MACD: Sell Signal | Dec 20, 2021 | 4 years ago |
| RSI: Overbought | Dec 9, 2021 | 4 years ago |
| RSI: Overbought | Nov 24, 2021 | 4 years ago |
Key statistics
- Market cap
- 292.40M
- Trailing P/E
- 6.07
- Forward P/E
- 20.19
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- 50-day average
- 10.14
- 200-day average
- 8.35
Analyst view
Consensus: none
Price target (mean) 0.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
May 2, 2022
Expected May 2, 2022. Consensus EPS estimate 0.00.
Financials — quick view
HBP Revenue — quarterly 272.70M
HBP Net income — quarterly 15.50M
HBP EPS — quarterly 0.56
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 2, 2022 | Mar 1, 2022 | 0.00 | — | — | — |
| Mar 2, 2022 | Dec 1, 2021 | 0.00 | — | — | — |
| Nov 3, 2021 | Sep 1, 2021 | 0.00 | — | — | — |
| Jul 28, 2021 | Jun 1, 2021 | 0.00 | — | — | — |
| May 3, 2021 | Mar 1, 2021 | 0.00 | — | — | — |
| Mar 1, 2021 | Dec 1, 2020 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2017 | Singular Research | init | — | Buy |
News
- Helix BioPharma (TSE:HBP) Reaches New 12-Month Low – Here’s What Happened
- Helix BioPharma Corp. Appoints Markus Loeffler, MD, MBA, as Chief Medical Officer to Support Next Phase of Clinical Development
- Helix Biopharma Corp. Announces Board Composition Changes
- Helix BioPharma Corp. Strengthens Executive Leadership to Support U.S. Listing Strategy and Next Phase of Clinical Development
- Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026
- Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures
- Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options
- Helix BioPharma (TSE:HBP) Stock Passes Above Fifty Day Moving Average – Should You Sell?
- Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026
- Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases
Your note
Sign in to keep a note on HBP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| FURIO ROBERT | Chief Operating Officer | Stock Award(Grant) | Jan 25, 2021 | 324,047 |
| GLASS DONALD L | Director | Stock Award(Grant) | Jan 25, 2021 | 204,570 |
| HIBBERD JAMES F | Director | Stock Award(Grant) | Jan 25, 2021 | 85,697 |
| HOAGLAND GINA GALGANO | Director | Stock Award(Grant) | Jan 25, 2021 | 70,099 |
| KEIPP PHILIP W | Chief Financial Officer | Stock Award(Grant) | Jan 25, 2021 | 287,930 |
| LARMON PATRICK L | Director | Stock Award(Grant) | Jan 25, 2021 | 87,095 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Susquehanna Fundamental Investments, LLC | 0.11% | 29,483 | 315.47K | Mar 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.20% | 600,943 | 6.43M | Mar 30, 2022 |
| Vanguard Extended Market Index Fund | 1.07% | 292,514 | 3.13M | Mar 30, 2022 |
| DFA U.S. Small Cap Series | 0.82% | 224,969 | 2.41M | Apr 29, 2022 |
| IndexIQ Tr-IQ Merger Arbitrage ETF | 0.54% | 146,853 | 1.57M | Apr 29, 2022 |
| Fidelity Extended Market Index Fund | 0.40% | 110,658 | 1.18M | Apr 29, 2022 |
| Highland Fds I-NexPoint Merger Arbitrage Fund | 0.35% | 96,889 | 1.04M | Mar 30, 2022 |